Annotation categories | Glaucoma | T2DM |
---|---|---|
AggregationMethod | 0.89 | 0.41 |
AllocationRatio | 0.91 | 0.00 |
Author | 0.97 | 0.98 |
BaseLineValue | 0.98 | 0.86 |
BioAndMedicalUnit | 0.89 | 0.81 |
ChangeValue | 0.96 | 0.77 |
ConclusionComment | 0.96 | 0.92 |
ConflictInterest | 0.00 | 0.00 |
Country | 0.93 | 0.87 |
CTAnalysisApproach | 0.26 | 0.19 |
CTDesign | 0.85 | 0.86 |
DeliveryMethod | 0.82 | 0.52 |
DiffGroupValues | 0.71 | 0.78 |
DisorderOrSyndrome | 0.93 | 0.98 |
DoseDescription | – | 0.41 |
DoseValue | 0.96 | 0.62 |
Drug | 0.83 | 0.91 |
Duration | 0.72 | 0.82 |
EndPointDescription | 0.79 | 0.77 |
Ethnicity | 0.83 | 0.86 |
Frequency | 0.92 | 0.92 |
Gender | – | 0.61 |
Journal | 0.97 | 0.94 |
MeasurementDevice | 0.19 | 0.00 |
ObjectiveDescription | 0.83 | 0.88 |
ObservedResult | 0.25 | 0.06 |
PMID | 0.98 | 1.00 |
Precondition | 0.47 | 0.66 |
PublicationYear | 0.95 | 0.98 |
RelativeChangeValue | 0.97 | 0.77 |
RelativeTime | 0.32 | 0.71 |
ResultMeasuredValue | 0.93 | 0.82 |
SubGroupDescription | 0.23 | 0.46 |
TimePoint | 0.46 | 0.71 |
Title | 0.95 | 0.98 |
Avg. Kappa | 0.74 | 0.68 |